GET THE APP

Synthesis and Biological evaluation Of Some New Benzoyl Pyrazole Derivatives bearing a 6,8-Dibromo-2-methylquinazolin-4-one Moiety

Der Pharma Chemica
Journal for Medicinal Chemistry, Pharmaceutical Chemistry, Pharmaceutical Sciences and Computational Chemistry

ISSN: 0975-413X
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission Systemof respective journal.

Research - Der Pharma Chemica ( 2022) Volume 14, Issue 2

Synthesis and Biological evaluation Of Some New Benzoyl Pyrazole Derivatives bearing a 6,8-Dibromo-2-methylquinazolin-4-one Moiety

Komal Savaliya1* and Pankaj S. Patel2
 
1Centre of Education, Indian Institute of Teacher Education, Gandhinagar, 382016, India (Assistant Professor, Indian Institute of Teacher Education-Gandhinagar), India
2Department of Chemistry, Sheth L.H. Science College, Mansa-382845, (Gujarat) India (Associate professer, Gujarat University, Ahmedabad), India
 
*Corresponding Author:
Komal Savaliya, Centre of Education, Indian Institute of Teacher Education, Gandhinagar, 382016, India, Email: komalsavaliya16@gmail.com

Received: 10-Jan-2022, Manuscript No. dpc-22-51453; Accepted Date: Jan 12, 2022 ; Editor assigned: 12-Jan-2022, Pre QC No. dpc-22-51453; Reviewed: 26-Jan-2022, QC No. dpc-22-51453; Revised: 31-Jan-2022, Manuscript No. dpc-22-51453; Published: 07-Feb-2022

Abstract

A new series of 3-[4-(1-benzoyl-5-(substitutedphenyl)-4,5-dihydro-pyrazol-3-yl)phenyl]-6,8-dibromo-2-methylquinazolin-4-one have been synthesized by the condensation reaction of 6,8-dibromo-3-{4-[5-(substitutedphenyl)-4,5-dihydro-pyrazol-3-yl]phenyl}-2-methylquinazolin-4-one with benzoyl chloride by using pyridine as a solvent. The intermediate have been synthesized by refluxation of 6,8-dibromo-3-{4-[3-(substitutedphenyl)prop-2-enoyl]phenyl}-2-methylquinazolin-4-one (0.01M) and 99% hydrazine hydrate (0.015M) by using ethanol (50ml) as a solvent with various aldehydes. The chemical structures of synthesized benzoyl pyrazoline derivatives were characterized by their IR, NMR and spectral data. The newly synthesized compounds were screened for their antibacterial and antifungal activities by Agar Cup method.

Keywords

Condensation; Benzoyl pyrazolines; Chalcone; antibacterial activity; Agar Cup method

Introduction

The heterocyclic compounds have a great importance in medicinal chemistry and play an important role in regulating biological process. One of the most important heterocycles in medicinal chemistry are quinazolines possessing wide spectrum of biological properties like Quinazolin-4(3H)-one are a class of fused hetero-cycles that are of considerable interest on account of the diverse range of their biological properties. Much attention has been paid to the synthesis of heterocyclic compounds bearing nitrogen containing ring system like pyrazoline mainly due to their higher pharmacological activity. Pyrazole is an unsaturated five-membered ring containing two adjacent nitrogen atoms as represented by the molecular formula C3H4N2. The noun pyrazole was given for the first time by Ludwig Knorr in 1883 [1]. The first natural pyrazole, 1-pyrazolyl-alanine was isolated from seeds of watermelons [2] (Figure 1).

derpharmachemica-Pyrazoles

Figure 1: Pyrazoles

Pyrazole and its derivatives have great interest in agrochemical, pharmaceutical, and chemical industries [3,4]. Pyrazolines are known to have anticancer [5], cytotoxic [6], antifungal [7], antitubercular [8], antioxidant [9]. Some pyrazolines are also reported to have anti-inflammatory, antidiabetic, anesthetic and analgesic properties [10-12]. The main skeletal of pyrazole and its related structures can be reported as important building blocks in organic synthetic for the design of a variety of biologically active compounds [13,14].

Materials and Methods

All reagents were of analytical reagent grade and were used without further purification. All the product were synthesized and characterized by their spectral analysis. All Melting points were determined by open capillary tube and are uncorrected. The IR spectra were recorded on Bruker Model; Alpha, Laser Class1, made in Germany and Brooker instrument was used for NMR Spectroscopy and (CH3)4Si (tetramethyl silane) used as internal standard and DMSO was used as a solvent. Purity of the compounds was checked by TLC on silica-G plates. Antimicrobial activities were tested by Agar Cup method. Standard drugs like Streptomycin and Fluconazole were used for the comparison purpose.

Result and Discussions

Preparation of 6, 8-dibromo-3-{4-[5-(substitutedphenyl)-4,5-dihydro-pyrazol-3-yl]phenyl}-2-methyl quinazolin-4-one (KS-1a-1j)

A mixture of 6,8-dibromo-3-{4-[3-(substitutedphenyl)prop-2-enoyl]phenyl}-2-methylquinazolin-4-one (0.01M) and 99% hydrazine hydrate (0.015M) in ethanol (50ml) refluxed gently for 3 hours. Then the mixture was concentrated and allowed to cool. The resulting solid was filtered, washed with ethanol and recrystallized from ethanol. 1HNMR (DMSO); (KS-1a): δ ppm 2.507, Singlet (3H) (-CH3), 3.368, Doublet(2H) (-CH2), 3.942 Triplet (1H) (-CH<), 7.377, Singlet (1H) (-NH), 7.277-8.340, Multiplet (10H) (Ar-H). 1HNMR (DMSO); (KS-1g): δ ppm 2.505, Singlet (3H) (-CH3), 3.355, Doublet(2H) (-CH2), 3.959 Triplet (1H) (-CH<), 7.379, Singlet (1H) (-NH), 7.379-8.411, Multiplet (10H) (Ar-H), 9.659, Singlet(1H) (-OH). IR(KBr); KS-1f (cm-1): 3379 (>NH-), 3269 (-OH), 3029 ( =C-H ), 2965 (-C-H Stretching), 1671 (>C=O Stretching), 1587 (>C=N stretching), 1503 (>C=C< Aromatic), 1442 (-CH2 bending) , 1402 (-CH3), 1304 (C-N), 1264 (N-N), 1169 (C-O-C) , 535 (C-Br). IR(KBr); KS-1i (cm-1): 3357 (>NH-), 3087 (=C-H ), 2906 (-C-H Stretching), 1662 (>C=O Stretching), 1587 (>C=N stretching), 1507 (>C=C< Aromatic), 1443 (-CH2 bending), 1420 (-CH3), 1294 (C-N), 1249 (N-N), 1168 (C-O-C), 548 (C-Br) (Scheme 1) (Tables 1and 2).

derpharmachemica-Reaction

Scheme 1: Reaction scheme

Table 1: Physical constant of 3-[4-(1-benzoyl-5-(substitutedphenyl)-4,5-dihydro-pyrazol-3-yl)phenyl]-6,8-dibromo-2-methyquinazolin-4-one

  % carbon % Nitrogen % Hydrogen
Sr No Sub. No. R M.F. Mol.Wt
(g/m)
Yield
%
M.P.C Found Calcd Found Calcd Found Calcd
1 KS-2a -2-Cl C31H21Br2ClN4O2 676.78 65 170 55.00 55.01 8.27 8.28 3.12 3.13
2 KS-2b -4-Cl C31H21Br2ClN4O2 676.78 78 190 55.01 55.01 8.24 8.28 3.12 3.13
3 KS-2c -3,4-(OCH3)2 C33H26Br2N4O4 702.39 58 136 56.41 56.43 7.97 7.98 3.72 3.73
4 KS-2d -H C31H22Br2N4O2 642.33 69 158 57.95 57.96 8.72 8.72 3.43 3.45
5 KS-2e -2-OH C31H22Br2N4O3 658.33 73 165 56.53 56.56 8.50 8.51 3.32 3.37
6 KS-2f -4-OH-3- OCH3 C32H24Br2N4O4 688.36 78 190 55.81 55.83 8.14 8.14 3.51 3.51
7 KS-2g -4-OH C31H22Br2N4O3 658.33 77 143 56.52 56.56 8.50 8.51 3.36 3.37
8 KS-2h -4-N(CH3)2 C33H27Br2N5O2 685.40 72 205 57.83 57.83 10.21 10.22 3.97 3.97
9 KS-2i -4-OCH3 C32H24Br2N4O3 672.36 68 165 57.12 57.16 8.32 8.33 3.6 3.6
10 KS-2j -3-NO2 C31H21Br2N5O4 687.33 70 150 54.16 54.17 10.16 10.19 3.05 3.08

Table 2: Antimicrobial activity of 3-[4-(1-benzoyl-5-(substitutedphenyl)-4,5-dihydro-pyrazol-3-yl)phenyl]-6,8-dibromo-2-methylquinazolin-4-one

SR No COMP NO R Zone of inhibition in mm
Antibactrerial Activity Antifungal
Activity
S. aureus E.coli Aspergillue niger Saccharomyces
1 KS-2a 2-Cl 32 28 19 18
2 KS-2b 4-Cl 28 26 23 20
3 KS-2c -3,4-(OCH3)2 20 NA 20 16
4 KS-2d -H 27 27 18 NA
5 KS-2e -2-OH 30 25 12 25
6 KS-2f -4-OH-3-OCH3 28 28 19 19
7 KS-2g -4-OH 30 28 18 17
8 KS-2h -4-N(CH3)2 27 18 12 15
9 KS-2i -4-OCH3 28 30 14 18
10 KS-2j -3-NO2 20 28 18 14

Preparation of 3-[4-(1-benzoyl-5-(substitutedphenyl)-4,5-dihydro-pyrazol-3-yl)phenyl]-6,8-dibromo-2-methylquinazolin-4-one (2a-2j)

A mixture of 6,8-dibromo-3-{4-[5-(2-substitutedphenyl)-4,5-dihydro-pyrazol-3-yl]phenyl}-2-methylquinazolin-4-one (0.001M) and benzoyl chloride (0.0011M) dissolved in dry pyridine (25ml) and stirred at room temperature for 1 hours, after which the reaction mixture treated with cold dilute HCl (2N). The resulting solid was filtered and washed successively with water, cold NaOH (2%) and water, and recrystallized from glacial acetic acid.

1HNMR (DMSO); (KS-2a): δ ppm 2.515, Singlet (3H) (-CH3), 3.388, Doublet(2H) (-CH2), 3.961, Triplet (1H) (-CH<), 7.492-7.971, Multiplet (15H) (Ar-H).

1HNMR (DMSO); (KS-2i): δ ppm 2.513, Singlet (3H) (-CH3), 3.352, Doublet(2H) (-CH2), 3.744, Singlet (3H) (-OCH3), 3.973, Triplet (1H) (-CH<), 7.491-7.969, Multiplet (15H).

IR(KBr); KS-2a (cm-1): 3044 (=C-H), 2969 (-C-H stretching), 1681 (>C=O stretching), 1580 (>C=N stretching), 1494 (>C=C< Aromatic), 1451 (-CH2 bending), 1419 (-CH3), 1323 (C-N), 1288 (N-N), 704 (C-Cl), 534 (C-Br). IR(KBr); KS-2c (cm-1): 3051 (=C-H), 2938 (-C-H stretching), 1666 (>C=O stretching), 1584 (>C=N stretching), 1510 (>C=C< Aromatic), 1445 (-CH2 bending), 1415 (-CH3), 1312 (C-N), 1257 (N-N), 1174(C-O-C), 545(C-Br) (Figure 2).

derpharmachemica-Interpretation

Figure 2: IR and NMR Interpretation of various compounds

derpharmachemica-Antimicrobial

Figure 3: Antimicrobial activity of 3-[4-(1-benzoyl-5-(substitutedphenyl)-4,5-dihydro-pyrazol-3-yl)phenyl]-6,8-dibromo-2-methylquinazolin-4-one

Anti bacterialactivity

A short review of results of anti-bacterial screening of the compounds of this section is mention here.

Against Staphylococcus aureus

Over all analysis of the screening result suggest KS-2a showed good anti-bacterial activity than the standard test-drug like Streptomycin also. Hence these compounds should be further tested under various conditions for their pharmaceutical applications. Minimum antibacterial activity was shown by the compounds 2c and 2j against S. aureus.

Against Escherichia Coli

From screening results, compound 2a, 2f, 2g and 2j were found to possess maximum antibacterial activity against Escherichia Coli. The minimum antifungal activity was shown by the compound KS-2h for E. Coli. 2c was found to be inactive against E. Coli.

Anti fungalactivity

A short review of results of anti-fungal screening of the compounds of this section is mention here.

Against Aspergillus Niger

Over all analysis of the screening result suggest that KS-2b showed good anti-fungal activity than the standard test-drug like Fluconazole also. Hence these compounds should be further tested under various conditions for their pharmaceutical applications. The minimum antifungal activity was shown by the compound KS-2e and 2h for Aspergillus Niger.

Against Saccharomyces

Over all analysis of the screening result suggest that KS-2e showed good anti-fungal activity than the standard test-drugs used for bio-assay. Hence these compounds should be further tested under various conditions for their pharmaceutical applications. 2d was found to be inactive against Saccharomyces. The minimum antifungal activity was shown by the compound KS-2j for Saccharomyces.

Conclusion

The Main objective of present research work was to synthesize, characterize and evaluate antimicrobial activities of the newly synthesized compounds with the help of analytical data such as 1H-NMR and IR. In conclusion, in present we prepared a series of 3-[4-(1-benzoyl-5-(substitutedphenyl)-4,5-dihydro-pyrazol-3-yl)phenyl]-6,8-dibromo-2-methylquinazolin-4-one. It is been observed that from the compounds tested, most of all were found to show good to moderate antibacterial and antifungal activity as compared to the standard drugs like Streptomycin and Fluconazole respectively.

Acknowledgements

We are grateful to the Principal Dr. Janakkumar R. Shukla and Management of Sheth L.H. Science College, Mansa for providing facilities for carrying out research work.

References

  1. Evelyn CS. Fec Publishing. 2012.
  2. [2] Eicher T and Hauptmann T. Wiley-VCH, Weinheim. 2003, p.7206.
  3. Google Scholar, Crossref

  4. Keter KF and Darkwa. J Biometals. 2012, 25: p. 9-21.
  5.   Indexed at, Google Scholar, Crossref

  6. Fustero S, Sanchez-Rosello M, Barrio P et al., Chem Rev. 2011, 111: p. 6984-7034.
  7. Indexed at, Google Scholar, Crossref

  8. Banjo Semire and Abel Kolawole Oyebamiji. Bulletin of Pharmaceutical Research. 2017, 7(3): p.1-9.
  9. Google Scholar, Crossref

  10. Esvet Akbas, Fatih Caglar Celikezen, Hasan Turkez et al., Cogent Chem. 2017, 134411: p.1-10.
  11. Google Scholar, Crossref

  12. Liu JJ, Zhao MY, Zhang X et al., Mini Rev Med Chem. 2013, 13: p.1957.
  13. Alagarsamy V, Solomon VR, Krishnamoorthy G et al., J Serb Chem Soc. 2015, 12: p.1471.
  14. Google Scholar, Crossref

  15. Sharath V, Kumar HV and Naik N. J Pharm Res. 2013, 6: p.785-790
  16. Google Scholar, Crossref

  17. Regaila HA, El-Bayanki AK and Hammad M. Egypt J Chem. 1979, p. 20.
  18. Krishna R B, Ranade R. Bhaithwal S P. and Parmar S, Eur. Med. J. Chem. Chimther; 1980, p.15567.
  19. Husain MI and Shukla S. Indian J. Chem. 1986, 25B: p. 983.
  20. Parmar NJ, Pansuriya BR, Labana BM et al., Eur J Org Chem. 2012, p. 5953-5964.
  21. Google Scholar, Crossref

  22. Ramiz MM, Hafiz IS, Reheim MA et al., J Chin Chem Soc. 2012, 59: p.72-80.

Select your language of interest to view the total content in your interested language

30+ Million Readerbase
SCImago Journal & Country Rank
Google Scholar citation report
Citations : 25868

Der Pharma Chemica received 25868 citations as per Google Scholar report

Der Pharma Chemica peer review process verified at publons
Der Pharma Chemica- Journals on pharmaceutical chemistry